INNOVATIONS / LEXI®

INEX IS ONE OF A HANDFUL OF COMPANIES IN THE WORLD THAT HAS SUCCESSFULLY PATENTED THE METHODOLOGY OF THE ISOLATION OF FETAL CELLS IN MATERNAL BLOOD. 

A STUDY FOUND THAT 72% OF WOMEN WOULD BE INTERESTED IN A NON INVASIVE PRENATAL DIAGNOSTIC TEST, AND THE SAFETY OF THEIR FETUS WAS THE SINGLE MOST IMPORTANT FACTOR IN CONSIDERING PRENATAL DIAGNOSIS1

The American College of Obstetrics and Gynaecology (ACOG) recommends that all pregnant women be offered both non-invasive screening and invasive diagnostic testing — yet women who are at high risk decline invasive methods of diagnostic testing because of their concerns on miscarriage.

Fetal cells in maternal blood represent the Holy Grail of prenatal diagnosis. The major challenge has been isolation of these cells from maternal blood owing to their rarity. Major advances have been made by INEX team in the field of Non Invasive Prenatal Diagnosis (NIPD), to isolate, recognise and analyse the fetal cells derived from maternal blood.

Current Non-Invasive Prenatal Test (NIPT) utilise fragmented circulating cell-free fetal DNA (cffDNA) in pregnant women, 
and makes inferences from the maternal blood.

The American College of Obstetrics and Gynaecology (ACOG) recommends that all pregnant women be offered both non-invasive screening and invasive diagnostic testing — yet women who are at high risk decline invasive methods of diagnostic testing because of their concerns on miscarriage.

Fetal cells in maternal blood represent the Holy Grail of prenatal diagnosis. The major challenge has been isolation of these cells from maternal blood owing to their rarity. Major advances have been made by INEX team in the field of Non Invasive Prenatal Diagnosis (NIPD), to isolate, recognise and analyse the fetal cells derived from maternal blood.

Current Non-Invasive Prenatal Test (NIPT) utilise fragmented circulating cell-free fetal DNA (cffDNA) in pregnant women,
and makes inferences from the maternal blood.

Source:
1. Noninvasive Prenatal Diagnosis: Pregnant Women’s Interest and Expected Uptake Reana Tischler,1 Louanne Hudgins,2 Yair J. Blumenfeld,3 Henry T. Greely,1,4,5 and Kelly E. Ormond1,5

 INEX has been working with National University of Singapore (NUS) and Agency of Science Technology and Research (A*STAR, Singapore) to develop LEXI®, and is one of a handful of companies in the world that has successfully patented the methodology of the isolation of fetal cells in maternal blood globally.  

INEX INNOVATE PTE. LTD

1 Science Park Road

#04-10 The Capricorn

Singapore 117528

CALL  +65 6773 0698

FAX   +65 6873 0240

© 2020 INEX INNOVATE PTE LTD